I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Carlos Alban Biography and Net Worth

Vice Chairman of AbbVie

Carlos Alban is Vice Chairman, Chief Commercial Officer of the Company. Mr. Alban is AbbVie's Executive Vice President, Commercial Operations. He served as Abbott's Senior Vice President, Proprietary Pharmaceutical Products, Global Commercial Operations from 2011 to 2012, as Senior Vice President, International Pharmaceuticals from 2009 to 2011, as Vice President, Western Europe and Canada from 2007 to 2009, and as Vice President, European Operations from 2006 to 2007. Mr. Alban joined Abbott in 1986.

What is Carlos Alban's net worth?: The estimated net worth of Carlos Alban is at least $24.21 million as of July 7th, 2020. Mr. Alban owns 137,899 shares of AbbVie stock worth more than $24,212,306 as of December 21st. This net worth approximation does not reflect any other assets that Mr. Alban may own. Learn More about Carlos Alban's net worth.
How do I contact Carlos Alban?: The corporate mailing address for Mr. Alban and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Carlos Alban's contact information.
Has Carlos Alban been buying or selling shares of AbbVie?: Carlos Alban has not been actively trading shares of AbbVie during the last quarter. Most recently, Carlos Alban sold 53,325 shares of the business's stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $100.00, for a transaction totalling $5,332,500.00. Following the completion of the sale, the insider now directly owns 137,899 shares of the company's stock, valued at $13,789,900. Learn More on Carlos Alban's trading history.
Who are AbbVie's active insiders?: AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Kevin Buckbee (SVP), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Scott Reents (CFO), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Perry Siatis (EVP), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.
Are insiders buying or selling shares of AbbVie?: During the last year, insiders at the sold shares 13 times. They sold a total of 737,381 shares worth more than $130,442,034.24. The most recent insider tranaction occured on December, 16th when SVP Kevin K Buckbee sold 1,800 shares worth more than $310,032.00. Insiders at AbbVie own 0.3% of the company. Learn More about insider trades at AbbVie.
Information on this page was last updated on 12/16/2024.

Carlos Alban Insider Trading History at AbbVie

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/7/2020	Sell	53,325	$100.00	$5,332,500.00	137,899
3/1/2018	Sell	83,574	$114.49	$9,568,387.26	133,026
6/14/2017	Sell	45,800	$70.00	$3,206,000.00	160,545
5/4/2017	Sell	43,000	$67.00	$2,881,000.00	114,745
5/10/2016	Sell	47,438	$63.52	$3,013,261.76	149,444
3/3/2014	Sell	2,882	$50.09	$144,359.38	205,138

Carlos Alban Buying and Selling Activity at AbbVie

AbbVie Company Overview

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Today's Range

Now: $175.58

$170.66

$176.80

50 Day Range

MA: $182.56

$164.91

$203.87

2 Week Range

Now: $175.58

$151.29

$207.32

Volume

17,695,750 shs

Average Volume

5,604,020 shs

Market Capitalization

$310.27 billion

P/E Ratio

60.97

Dividend Yield

3.54%

Beta

0.58

I was wrong. Dead wrong.

From Porter & Company | Ad